ImageneBio Inc (IMA)
ImageneBio Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $4.72, up 1.29% on the session, giving a market capitalisation of $53.2M. On trailing twelve-month figures it carries a trailing P/E of -0.91, a net margin of 0.0%. Its beta of 0.71 implies it has historically moved less than the broad market.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
ImageneBio Inc is most often compared with the following Healthcare names: